Cleveland Alzheimers Disease Research Center

克利夫兰阿尔茨海默病研究中心

• 批准号: 10675648
• 负责人: JAMES Bruce LEVERENZ
• 金额: $ 307.19万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10675648
• 关键词: Acceleration; Address; African American; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Autopsy; Behavioral; Biological Markers; Biology; Brain; Brain Diseases; Cessation of life; Clinic; Clinical; Cognitive; Collaborations; Collection; Communities; Consent; Data; Dementia; Dementia with Lewy Bodies; Development; Diagnosis; Disease; Disease Progression; Early identification; Enrollment; Ensure; Evaluation; Financial Support; Fostering; Foundations; Freezing; Funding; Genetic; Genetic Risk; Goals; Heterogeneity; Human; Image; Impairment; Individual; Infrastructure; Institution; International; Intervention; Laboratory Finding; Link; Magnetic Resonance Imaging; Medical center; Memory; Molecular; Monitor; Motor; National Institute on Aging; Ohio; Participant; Pathologic; Pathology; Persons; Phenotype; Physicians; Population; Professional Education; Research; Research Design; Research Personnel; Resources; Risk; Risk Factors; Scientist; Speed; Standardization; System; Tissue Sample; Tissues; Training; Translating; Translational Research; Translations; Underrepresented Populations; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; University Hospitals; Veterans; amyloid imaging; career; career development; cell repository; cohort; collaborative environment; community center; data management; data repository; demented; design; drug discovery; education research; ethnic minority; health disparity; high risk; improved; individualized medicine; insight; mild cognitive impairment; neuroimaging; neuropathology; next generation; novel therapeutics; outreach; participant retention; patient engagement; precision medicine; programs; protective factors; racial minority; recruit; shared repository; social stigma; statistics; success; targeted biomarker; therapeutic target; tool; translational therapeutics

PROJECT SUMMARY The Cleveland Alzheimer's Disease Research Center (CADRC) is a collaborative effort of physicians and investigators from Case Western Reserve University (CWRU), Cleveland Clinic Foundation (CCF), MetroHealth System (MHS), University Hospitals (UH), and the Louis Stokes Cleveland VA Medical Center (LSCVAMC), to foster excellence in research and facilitate discovery as an established National Institute on Aging (NIA) funded Alzheimer's Disease Research Center. The CADRC represents a rich clinical and research community and an estimated 220,000 Ohioans who suffer from Alzheimer's disease (AD) or AD-related dementias (ADRD). The CADRC has 8 Cores and a Research Education Component designed to create the foundation that will enhance the research efforts of the Northeast Ohio AD/ADRD research community, as well as add unique value to the national Alzheimer's Disease Research Centers (ADRC) program and other national and international research programs. The CADRC is focused on participants that will help us understand the pathobiology of clinical and pathological heterogeneity observed in dementia including atypical and amnestic AD, dementia with Lewy bodies, cognitively normal individuals with different levels of genetic risk for AD, and diversity of participant populations (Clinical and Outreach, Recruitment, and Engagement Cores). To support the CADRC goals, the focus will be on deep phenotyping of participants with longitudinal and systematic cognitive, behavioral and motor characterization (Clinical Core), genetic and biofluid biomarker collection and analysis (Biomarker Core), imaging (Neuroimaging Core), and autopsy after death (Neuropathology Core). Results will be shared with the research community in a timely and regular manner to allow other investigators to benefit from the CADRC efforts (Data Management and Statistics Core). In addition, the CADRC will train the next generation of investigators utilizing a rigorous and well-designed Research Education Component, support translation of new laboratory findings through the Translational Therapeutics Core, and support high risk/high gain projects through the developmental program as a part of the Administrative Core. The ultimate goals are to advance the precision medicine approach to dementia diagnosis and treatment, support the development of early stage investigators, assist all stages of investigators with tools for performing human-based research, and better engage underrepresented populations in AD/ADRD research.

项目总结 克利夫兰阿尔茨海默病研究中心(CADRC)是医生们共同努力的成果 以及凯斯西储大学(CWRU)、克利夫兰临床基金会(CCF)的调查人员， MetroHealth System(MHS)、大学医院(UH)和路易斯斯托克斯克利夫兰退伍军人医疗中心 (LSCVAMC)，以促进卓越的研究和促进发现，作为一个建立的国家研究所 老龄化(NIA)资助阿尔茨海默病研究中心。CADRC代表了丰富的临床和研究 社区和大约220,000名患有阿尔茨海默病(AD)或AD相关疾病的俄亥俄州人 痴呆(ADRD)。CADRC有8个核心和一个研究教育组件，旨在创建 基金会，也将加强俄亥俄州东北部AD/ADRD研究社区的研究努力 AS为国家阿尔茨海默病研究中心(ADRC)计划和其他项目增加了独特的价值 国家和国际研究计划。CADRC专注于将帮助我们的参与者 了解痴呆的临床和病理异质性的病理生物学，包括非典型痴呆症 遗忘性阿尔茨海默病、路易体痴呆、具有不同遗传风险水平的认知正常个体 对于AD，以及参与人群的多样性(临床和外联、招聘和参与核心)。 为了支持CADRC的目标，重点将放在参与者的深度表型上，这些参与者的纵向和 系统性认知、行为和运动特征(临床核心)、遗传和生物流体生物标记物 收集和分析(Biomarker核心)、成像(神经成像核心)和死后尸检 (神经病理学核心)。研究结果将及时和定期地与研究界分享，以 允许其他调查人员受益于发审委的工作(数据管理和统计核心)。在……里面 此外，CADRC将培训下一代调查人员，利用严格和精心设计的 研究教育部分，通过翻译支持新的实验室发现的翻译 治疗核心，并通过发展计划支持高风险/高收益项目，作为 管理核心。最终目标是推进治疗痴呆症的精准医学方法 诊断和治疗，支持早期调查人员的发展，协助所有阶段的调查人员 利用工具进行以人为本的研究，并更好地让未被充分代表的人群参与 AD/ADRD研究。

项目成果

High-resolution functional connectivity of the default mode network in young adults with down syndrome.

• DOI: 10.1007/s11682-020-00399-z
• 发表时间: 2021-08
• 期刊: Brain imaging and behavior
• 影响因子: 3.2
• 作者: Koenig KA;Bekris LM;Ruedrich S;Weber GE;Khrestian M;Oh SH;Kim S;Wang ZI;Leverenz JB
• 通讯作者: Leverenz JB

Increased Risk of Dementia Among Veterans With Bipolar Disorder or Schizophrenia Receiving Care in the VA Health System.

在VA卫生系统中接受护理的双相情感障碍或精神分裂症的退伍军人中痴呆症的风险增加。

• DOI: 10.1176/appi.ps.201900325
• 发表时间: 2020-10-01
• 期刊: Psychiatric services (Washington, D.C.)
• 作者: Ahearn EP;Szymanski BR;Chen P;Sajatovic M;Katz IR;McCarthy JF
• 通讯作者: McCarthy JF

Overcoming barriers to informed consent in neurological research: Perspectives from a national survey.

• DOI: 10.1177/17470161221131497
• 发表时间: 2023-01
• 期刊: RESEARCH ETHICS
• 影响因子: 1.7
• 作者: Sankary, Lauren R.;Zelinsky, Megan E.;Ford, Paul J.;Blackstone, Eric C.;Fox, Robert J.
• 通讯作者: Fox, Robert J.

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery.

• DOI: 10.1186/s13195-020-00760-w
• 发表时间: 2021-01-13
• 期刊: Alzheimer's research & therapy
• 作者: Zhou Y;Fang J;Bekris LM;Kim YH;Pieper AA;Leverenz JB;Cummings J;Cheng F
• 通讯作者: Cheng F

Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

利用当阿尔茨海默氏症的药物重新利用的内聚型和网络医学。

• DOI: 10.1002/med.21709
• 发表时间: 2020-11
• 期刊: Medicinal research reviews
• 影响因子: 13.3
• 作者: Fang J;Pieper AA;Nussinov R;Lee G;Bekris L;Leverenz JB;Cummings J;Cheng F
• 通讯作者: Cheng F